Patient's compliance with allergen immunotherapy

Patient Preference and Adherence

Volumn 2, Issue , 2008, Pages 247-251

  Incorvaia, Cristoforo ^a   Mauro, Marina ^b   Ridolo, Erminia ^c   Puccinelli, Paola ^d   Liuzzo, Massimiliano ^d   Scurati, Silvia ^d   Frati, Franco ^d,e  

^a ICP Hospital   (Italy)

^b SANT ANNA HOSPITAL   (Italy)

^c University Department of Clinical and Experimental Medicine   (Italy)

^d Medical and Scientific Department   (Italy)

^e UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Adherence; Allergen immunotherapy; Compliance; Local nasal; Subcutaneous; Sublingual

Indexed keywords

EID: 68949118966     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S3806     Document Type: Review

References (29)

1. André C., Vatrinet C, Galvain S, et al. 2000. Safety of sublingual-swallow immunotherapy in children and adults. Int Arch Allergy Immunol, 121:229-34.
2. Bender B., Milgrom H, Rand C. 1997. Nonadherence in asthmatic patients: is there a solution to the problem? Ann Allergy Asthma Immunol, 79:177-85.
3. Billups S. J, Malone DC, Carter BL. 2000. The relationship between drug therapy noncompliance and patient characteristics, health-related quality of life, and health care costs. Pharmacotherapy, 20:941-9.
4. Blackwell B. 1973. Patient compliance. N Engl J Med, 289:249-52.
5. Blaiss M.S. 2003. Important aspects in management of allergic rhinitis: compliance, cost, and quality of life. Allergy Asthma Proc, 24:231-8.
6. Bousquet J., Lockey RF, Malling HJ. 1998. WHO Position Paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy, 53(Suppl 44):4-30.
7. Bousquet J., van Cauwenberge P (eds). 2001. Allergic Rhinitis and its Impact on Asthma (ARIA). Position Paper endorsed by WHO. J Allergy Clin Immunol, 108(Suppl 5):147-334.
8. Cadario G., Ciprandi G, Di Cara G, et al. 2008. Comparison between continuous or intermittent schedules of sublingual immunotherapy for house dust mites: effects on compliance, patients satisfaction, quality of life and safety. Int J Immunopathol Pharmacol, 21:471-3.
9. Canonica G. W, Passalacqua G. 2003. Noninjection routes for immunotherapy. J Allergy Clin Immunol, 111:437-48.
10. Cohn J. R, Pizzi A. 1993. Determinants of patient compliance with allergen immunotherapy. J Allergy Clin Immunol, 91:734-7.
11. Durham S. R, Walker SM, Varga EM, et al. 1999. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med, 341:468-75.
12. Frati F., Puccinelli P, Valle C, et al. 2007. Evidence-based criteria for allergen immunotherapy. It J Allergy Clin Immunol, 17:143-7.
13. Frew A.J. 2003. Immunotherapy of allergic disease. J Allergy Clin Immunol,111:S712-9.
14. Haynes R.B. Sackett DL, Taylor DW. 1979. Compliance in healthcare. Baltimore, MD: Johns Hopkins University Press.
15. Incorvaia C., Rapetti A, Megali R, et al. 2003. Comparison of compliance to high dose SLIT in patients with different grade of of instruction on treatment management [abstract]. XXII Congress of the European Academy of Allergology and Clinical Immunology. p. 4.
16. Lombardi C., Gani F, Landi M, et al. 2004. Quantitative assessment of the adherence to sublingual immunotherapy. J Allergy Clin Immunol, 113:1219-20.
17. Lower T., Henry J, Mandik L, et al. 1993. Compliance with allergen immunotherapy. Ann Allergy Asthma Immunol, 70:480-2.
18. Marogna M., Spadolini I, Massolo A, et al. 2004. Randomized controlled open study of sublingual immunotherapy for respiratory allergy in real-life: clinical efficacy and more. Allergy, 59:1205-10.
19. Milgrom H., Bender B, Ackerson L, et al. 1996. Noncompliance and treatment failure in children with asthma. J Allergy Clin Immunol, 98:1051-7.
20. More D. R, Hagan LL. 2002. Factors affecting compliance with allergen immunotherapy at a military medical center. Ann Allergy Asthma Immunol, 88:391-4.
21. Novembre E., Galli E, Landi F, et al. 2004. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol, 114:851-7.
22. Pajno G. B, Vita D, Caminiti L, et al. 2005. Children's compliance with allergen immunotherapy according to administration routes. J Allergy Clin Immunol, 116:1380-1.
23. Passalacqua G., Musarra A, Pecora S, et al. 2006. Quantitative assessment of the compliance with once-daily sublingual immunotherapy regimen in real life (EASY project: Evaluation of A novel SLIT formulation during a year. J Allergy Clin Immunol, 117:946-8.
24. Passalacqua G., Musarra A, Pecora S, et al. 2007. Quantitative assessment of the compliance with once daily sublingual immunotherapy in children (EASY project: Evaluation of A novel SLIT formulation during a Year). Pediatr Allergy Immunol, 18:56-62.
25. Rhodes B.J. 1999. Patient dropouts before completion of optimal dose, multiple allergen immunotherapy. Ann Allergy Asthma Immunol, 82:281-6.
26. Ruiz F. J, Jimenez A, Cocoletzi J, et al. 1997. Compliance with and abandonment of immunotherapy. Rev Alerg Mex, 44:42-4.
27. Sade K., Berkun Y, Dolev Z, et al. 2003. Knowledge and expectations of patients receiving aerallergen immunotherapy. Ann Allergy Asthma Immunol, 91:444-8.
28. Tinkelman D., Smith F, Cole WQ, et al. 1995. Compliance with an allergen immunotherapy regime. Ann Allergy Asthma Immunol, 74:241-6.
29. Wilson D. R, Torres-Lima M, Durham SR. 2005. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy, 60:4-12.